Molecular pathogenesis of Ewing sarcoma: New therapeutic and transcriptional targets

Annual Review of Pathology: Mechanisms of Disease

Volumn 7, Issue , 2012, Pages 145-159

  Lessnick, Stephen L ^a   Ladanyi, Marc ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chromatin immunoprecipitation; Chromosomal translocation; EWS FLI1; Oncogenesis; Stem cells; Transcription

Indexed keywords

NUCLEAR RECEPTOR DAX 1; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN FL11; RNA BINDING PROTEIN EWS; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C RECEPTOR; SONIC HEDGEHOG PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR NKX2.2; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG;

CELL PROLIFERATION; CELL STRAIN 3T3; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; DNA BINDING; EWING SARCOMA; GENE EXPRESSION; GENE FUSION; GENE IDENTIFICATION; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; MESENCHYMAL STEM CELL; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

ANIMALS; BONE NEOPLASMS; CHROMATIN IMMUNOPRECIPITATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MESENCHYMAL STROMAL CELLS; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEIN C-FLI-1; RNA-BINDING PROTEIN EWS; SARCOMA, EWING; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC;

EID: 84856870979     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-011110-130237     Document Type: Review

References (108)

1. Ewing J. 1913. Endothelioma of lymph nodes. J. Med. Res. 28:1-40
2. Aurias A. 1983. Chromosomal translocation in Ewing's sarcoma. N. Engl. J. Med. 309:496-97
3. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, et al. 1992. Gene fusion with an ETS DNA- binding domain caused by chromosome translocation in human tumours. Nature 359:162-65
4. Balamuth NJ, Womer RB. 2010. Ewing's sarcoma. Lancet Oncol. 11:184-92
5. Kovar H. 2010. Downstream EWS/FLI1-upstream Ewing's sarcoma. Genome Med. 2:8
6. Ordonez JL, Osuna D, Herrero D, de Alava E, Madoz-Gurpide J. 2009. Advances in Ewing's sarcoma research:Where are we now and what lies ahead? Cancer Res. 69:7140-50
7. Riggi N, Cironi L, Suva ML, Stamenkovic I. 2007. Sarcomas: genetics, signalling, and cellular origins. Part 1: The fellowship of TET. J. Pathol. 213:4-20 (Pubitemid 47354561)
8. Le Deley MC, Delattre O, Schaefer KL, Burchill SA, Koehler G, et al. 2010. Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J. Clin. Oncol. 28:1982-88
9. Sorensen PHB, Lessnick SL, Lopez-Terrada D, Liu XF, Triche TJ, Denny CT. 1994. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat. Genet. 6:146-51 (Pubitemid 24188594)
10. van Doorninck JA, Ji L, Schaub B, Shimada H, Wing MR, et al. 2010. Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group. J. Clin. Oncol. 28:1989-94
11. Zucman J, Melot T, Desmaze C, Ghysdael J, Plougastel B, et al. 1993. Combinatorial generation of variable fusion proteins in the Ewing family of tumours. EMBO J. 12:4481-87 (Pubitemid 23330254)
12. Berg T, Kalsaas AH, Buechner J, Busund LT. 2009. Ewing sarcoma-peripheral neuroectodermal tumor of the kidney with a FUS-ERG fusion transcript. Cancer Genet. Cytogenet. 194:53-57
13. Ng TL, O'Sullivan MJ, Pallen CJ, Hayes M, Clarkson PW, et al. 2007. Ewing sarcoma with novel translocation t(2;16) producing an in-frame fusion of FUS and FEV. J. Mol. Diagn. 9:459-63 (Pubitemid 47434112)
14. Shing DC, McMullan DJ, Roberts P, Smith K, Chin SF, et al. 2003. FUS/ERG gene fusions in Ewing's tumors. Cancer Res. 63:4568-76 (Pubitemid 36951031)
15. Wang L, Bhargava R, Zheng T, Wexler LH, Collins MH, et al. 2007. Undifferentiated small round cell sarcomas with rare EWS gene fusions. Identification of a novel EWS-SP3 fusion and of additional cases with the EWS-ETV1 and EWS-FEV fusions. J. Mol. Diagn. 9:498-509 (Pubitemid 47434117)
16. Szuhai K, Ijszenga M, de Jong D, Karseladze A, Tanke HJ, Hogendoorn PC. 2009. The NFATc2 gene is involved in a novel cloned translocation in a Ewing sarcoma variant that couples its function in immunology to oncology. Clin. Cancer Res. 15:2259-68
17. Sankar S, Lessnick SL. 2011. Promiscuous partnerships in Ewing's sarcoma. Cancer Genet. 204:351-65
18. Arvand A, Denny CT. 2001. Biology ofEWS/ETS fusions inEwing's family tumors. Oncogene 20:5747-54 (Pubitemid 32928112)
19. LadanyiM. 2002. EWS-FLI1 and Ewing's sarcoma: recent molecular data and new insights. Cancer Biol. Ther. 1:330-36
20. Aman P, Panagopoulos I, Lassen C, Fioretos T, Mencinger M, et al. 1996. Expression patterns of the human sarcoma-associated genes FUS and EWS and the genomic structure of FUS. Genomics 37:1-8 (Pubitemid 26341827)
21. Plougastel B, Zucman J, Peter M, Thomas G, DelattreO. 1993. Genomic structure of the EWS gene and its relationship to EWSR1, a site of tumor-associated chromosome translocation. Genomics 18:609-15 (Pubitemid 24021079)
22. Truong AH, BenDavid Y. 2000. The role of FLI-1 in normal cell function andmalignant transformation. Oncogene 19:6482-89 (Pubitemid 32108438)
23. May WA, Gishizky ML, Lessnick SL, Lunsford LB, Lewis BC, et al. 1993. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc. Natl. Acad. Sci. USA 90:5752-56 (Pubitemid 23176240)
24. MayWA, Lessnick SL, Braun BS, Klemsz M, Lewis BC, et al. 1993. The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol. Cell Biol. 13:7393-98 (Pubitemid 23354263)
25. Arvand A, Bastians H, Welford SM, Thompson AD, Ruderman JV, Denny CT. 1998. EWS/FLI1 up regulates mE2-C, a cyclin-selective ubiquitin conjugating enzyme involved in cyclin B destruction. Oncogene 17:2039-45 (Pubitemid 28499330)
26. Braun BS, Frieden R, Lessnick SL, May WA, Denny CT. 1995. Identification of target genes for the Ewing's sarcoma EWS/FLI fusion protein by representational difference analysis. Mol. Cell Biol. 15:4623-30
27. Deneen B, Welford SM, Ho T, Hernandez F,Kurland I, Denny CT. 2003. PIM3 proto-oncogene kinase is a common transcriptional target of divergent EWS/ETS oncoproteins. Mol. Cell Biol. 23:3897-908 (Pubitemid 36597468)
28. MayWA, Arvand A, Thompson AD, Braun BS, Wright M, Denny CT. 1997. EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic. Nat. Genet. 17:495-97 (Pubitemid 27518406)
29. Thompson AD, Braun BS, Arvand A, Stewart SD, MayWA et al. 1996. EAT-2 is a novel SH2 domain containing protein that is upregulated by Ewing's sarcoma EWS/FLI1 fusion gene. Oncogene 13:2649-58 (Pubitemid 27046120)
30. Zwerner JP, May WA. 2001. PDGF-C is an EWS/FLI induced transforming growth factor in Ewing family tumors. Oncogene 20:626-33 (Pubitemid 32156187)
31. Braunreiter CL, Hancock JD, Coffin CM, Boucher KM, Lessnick SL. 2006. Expression of EWS-ETS fusions in NIH3T3 cells reveals significant differences to Ewing's sarcoma. Cell Cycle 5:2753-59 (Pubitemid 44901737)
32. Hancock JD, Lessnick SL. 2008. A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature. Cell Cycle 7:250-56 (Pubitemid 351366526)
33. Gangwal K, Sankar S, Hollenhorst PC, Kinsey M, Haroldsen SC, et al. 2008. Microsatellites as EWS/FLI response elements in Ewing's sarcoma. Proc. Natl. Acad. Sci. USA 105:10149-54
34. Owen LA, Lessnick SL. 2006. Identification of target genes in their native cellular context: an analysis of EWS/FLI in Ewing's sarcoma. Cell Cycle 5:2049-53 (Pubitemid 44553736)
35. Uren A, Merchant MS, Sun CJ, VitoloMI, Sun Y, et al. 2003. α-Platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells. Oncogene. 22:2334-42 (Pubitemid 36566788)
36. Hu-Lieskovan S, Zhang J, Wu L, Shimada H, Schofield DE, Triche TJ. 2005. EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumors. Cancer Res. 65:4633-44 (Pubitemid 40740799)
37. Lessnick SL, Dacwag CS, Golub TR. 2002. The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. Cancer Cell 1:393-401 (Pubitemid 41039140)
38. Riggi N, Suva ML, Suva D, Cironi L, Provero P, et al. 2008. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res. 68:2176-85 (Pubitemid 351521790)
39. Rorie CJ, Thomas VD, Chen P, Pierce HH, O'Bryan JP, Weissman BE. 2004. The EWS/FLI-1 fusion gene switches the differentiation program of neuroblastomas to Ewing sarcoma/peripheral primitive neuroectodermal tumors. Cancer Res. 64:1266-77 (Pubitemid 38235593)
40. Weiss R, Walz PH. 2009. Peripheral primitive neuroectodermal tumor in a lumbar vertebra and the liver of a dromedary camel (Camelus dromedarius). J. Comp. Pathol. 141:182-86
41. Huang HY, Illei PB, Zhao Z, Mazumdar M, Healey JH, et al. 2005. Ewing sarcomas with p53 mutations or p16/p14ARF homozygous deletions: a highly aggressive subset associated with poor chemoresponse. J. Clin. Oncol. 23:548-58 (Pubitemid 46224232)
42. Kovar H, Auinger A, Jug G, Aryee D, Zoubek A, et al. 1993. Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours. Oncogene 8:2683-90 (Pubitemid 23279096)
43. Ladanyi M, Lewis R, Jhanwar SC, Gerald W, Huvos AG, Healey JH. 1995. MDM2 and CDK4 gene amplification in Ewing's sarcoma. J. Pathol. 175:211-17
44. Ban J, Bennani-Baiti IM, Kauer M, Schaefer KL, Poremba C, et al. 2008. EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma. Cancer Res. 68:7100-9
45. Torchia EC, Jaishankar S, Baker SJ. 2003. Ewing tumor fusion proteins block the differentiation of pluripotent marrow stromal cells. Cancer Res. 63:3464-68 (Pubitemid 36793021)
46. Li XD, McGee-Lawrence ME, Decker M, Westendorf JJ. 2010. The Ewing's sarcoma fusion protein, EWS-FLI, binds Runx2 and blocks osteoblast differentiation. J. Cell. Biochem. 111:933-43
47. Eliazer S, Spencer J, Ye D, Olson E, Ilaria RL Jr. 2003. Alteration of mesodermal cell differentiation by EWS/FLI-1, the oncogene implicated in Ewing's sarcoma. Mol. Cell Biol. 23:482-92 (Pubitemid 36050543)
48. Feng B, Chen L. 2009. Review of mesenchymal stem cells and tumors: executioner or coconspirator? Cancer Biother. Radiopharm. 24:717-21
49. KauerM, Ban J, Kofler R, Walker B, Davis S, et al. 2009. A molecular function map of Ewing's sarcoma. PLoS ONE 4:e5415
50. Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, Delattre O. 2007. Mesenchymal stem cell features of Ewing tumors. Cancer Cell 11:421-29 (Pubitemid 46680428)
51. Riggi N, Cironi L, Provero P, SuvaML, Kaloulis K, et al. 2005. Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res. 65:11459-68 (Pubitemid 41821703)
52. Graf T, Enver T. 2009. Forcing cells to change lineages. Nature 462:587-94
53. Yamanaka S, Blau HM. 2010. Nuclear reprogramming to a pluripotent state by three approaches. Nature 465:704-12
54. Riggi N, Suva ML, De Vito C, Provero P, Stehle JC, et al. 2010. EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Genes Dev. 24:916-32
55. Richter GHS, Plehm S, Fasan A, Rossler S, Unland R, et al. 2009. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc. Natl. Acad. Sci. USA 106:5324-29
56. Fujino T, Nomura K, Ishikawa Y, Makino H, Umezawa A, et al. 2010. Function of EWS-POU5F1 in sarcomagenesis and tumor cell maintenance. Am. J. Pathol. 176:1973-82
57. Yamaguchi S, Yamazaki Y, Ishikawa Y, Noriyoshi KI, Mukai H, Nakamura T. 2005. EWSR1 is fused to POU5F1 in a bone tumor with translocation t(6;22)(p21;q12). Genes Chromosomes Cancer 43:217-22 (Pubitemid 40570743)
58. Antonescu CR, Zhang L, Chang NE, Pawel BR, TravisW, et al. 2010. EWSR1-POU5F1 fusion in soft tissuemyoepithelial tumors.Amolecular analysis of sixty-six cases, including soft tissue, bone, and visceral lesions, showing common involvement of the EWSR1 gene. Genes Chromosomes Cancer 49:1114-24
59. Moller E, Stenman G, Mandahl N ,Hamberg H, Molne L, et al. 2008. POU5F1, encoding a key regulator of stem cell pluripotency, is fused to EWSR1 in hidradenoma of the skin andmucoepidermoid carcinoma of the salivary glands. J. Pathol. 215:78-86 (Pubitemid 351619878)
60. Kovar H, Ban J, Pospisilova S. 2003. Potentials for RNAi in sarcoma research and therapy: Ewing's sarcoma as a model. Semin. Cancer Biol. 13:275-81 (Pubitemid 38160919)
61. Chansky HA, Barahmand-Pour F, Mei Q, Kahn-Farooqi W, Zielinska- Kwiatkowska A, et al. 2004. Targeting of EWS/FLI-1 by RNA interference attenuates the tumor phenotype of Ewing's sarcoma cells in vitro. J. Orthop. Res. 22:910-17 (Pubitemid 38756277)
62. Kinsey M, Smith R, Lessnick SL. 2006. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma. Mol. Cancer Res. 4:851-59 (Pubitemid 44877015)
63. Prieur A, Tirode F, Cohen P, Delattre O. 2004. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol. Cell Biol. 24:7275-83 (Pubitemid 39014452)
64. Smith R, Owen LA, Trem DJ, Wong JS, Whangbo JS, et al. 2006. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell 9:405-16 (Pubitemid 43668735)
65. Lessnick SL, Braun BS, Denny CT, May WA. 1995. Multiple domains mediate transformation by the Ewing's sarcoma EWS-FLI-1 fusion gene. Oncogene 10:423-31
66. Benini S, Zuntini M, Manara MC, Cohen P, Nicoletti G, et al. 2006. Insulin-like growth factor binding protein 3 as an anticancer molecule in Ewing's sarcoma. Int. J. Cancer 119:1039-46 (Pubitemid 44116910)
67. Cironi L, Riggi N, Provero P, Wolf N, Suva ML, et al. 2008. IGF1 is a common target gene of Ewing's sarcoma fusion proteins in mesenchymal progenitor cells. PLoS ONE 3:e 2634
68. McKinsey EL, Parrish JK, Irwin AE, Niemeyer BF, KernHB, et al. 2011. A novel oncogenicmechanism in Ewing sarcoma involving IGF pathway targeting by EWS/FLI1-regulated microRNAs. Oncogene. In press
69. Owen LA, Kowalewski AA, Lessnick SL. 2008.EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma. PLoS ONE 3:e1965
70. Doyle MJ, Loomis ZL, Sussel L. 2007. Nkx2.2-repressor activity is sufficient to specify α-cells and a small number of α-cells in the pancreatic islet. Development 134:515-23 (Pubitemid 46332488)
71. Chen G, Fernandez J, Mische S, Courey AJ. 1999. A functional interaction between the histone deacetylase Rpd3 and the corepressor groucho in Drosophila development. Genes Dev. 13:2218-30 (Pubitemid 29426727)
72. Keshelava N, Houghton PJ, Morton CL, Lock RB, Carol H, et al. 2009. Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. Pediatr. Blood Cancer 53:505-8
73. Briscoe J, Sussel L, Serup P, Hartigan-O'Connor D, Jessell TM, et al. 1999. Homeobox gene Nkx2.2 and specification of neuronal identity by graded sonic hedgehog signaling. Nature 398:622-27 (Pubitemid 29183690)
74. Zwerner JP, Joo J, Warner KL, Christensen L, Hu-Lieskovan S, et al. 2008. The EWS/FLI1 oncogenic transcription factor deregulates GLI1. Oncogene 27:3282-91 (Pubitemid 351733391)
75. Beauchamp E, Bulut G, Abaan O, Chen K, Merchant A, et al. 2009. GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein. J. Biol. Chem. 284:9074-82
76. Zanaria E, Muscatelli F, Bardoni B, Strom TM, Guioli S, et al. 1994. An unusual member of the nuclear hormone receptor superfamily responsible for X-linked adrenal hypoplasia congenita. Nature 372:635-41
77. Garcia-Aragoncillo E, Carrillo J, Lalli E, Agra N, Gomez-Lopez G, et al. 2008. DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells. Oncogene 27:6034-43
78. Savkur RS, Burris TP. 2004. The coactivator LXXLL nuclear receptor recognition motif. J. Pept. Res. 63:207-12 (Pubitemid 38496672)
79. Kinsey M, Smith R, Iyer AK, McCabe ER, Lessnick SL. 2009. EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma. Cancer Res. 69:9047-55
80. Guillon N, Tirode F, Boeva V, Zynovyev A, Barillot E, Delattre O. 2009. The oncogenic EWS-FLI1 protein binds in vivo GGAA microsatellite sequences with potential transcriptional activation function. PLoS ONE 4:e4932
81. Worch J, Cyrus J, Goldsby R, Matthay KK, Neuhaus J, DuBois SG. 2011. Racial differences in the incidence of mesenchymal tumors associated with EWSR1 translocation. Cancer Epidemiol. Biomarkers Prev. 20:449-53
82. Boeva V, Surdez D, Guillon N, Tirode F, Fejes AP, et al. 2010. De novo motif identification improves the accuracy of predicting transcription factor binding sites in ChIP-Seq data analysis. Nucleic Acids Res. 38:e126
83. Luo W, Gangwal K, Sankar S, Boucher KM, Thomas D, Lessnick SL. 2009. GSTM4 is a microsatellitecontainingEWS/ FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance. Oncogene 28:4126-32
84. Bachmaier R, Aryee DN, Jug G, Kauer M, Kreppel M, et al. 2009. O-GlcNAcylation is involved in the transcriptional activity of EWS-FLI1 in Ewing's sarcoma. Oncogene 28:1280-84
85. Petermann R, Mossier BM, Aryee DNT, Khazak V, Golemis EA, Kovar H. 1998. Oncogenic EWS-FLI1 interacts with hsRPB7, a subunit of human RNA polymerase II. Oncogene 17:603-10 (Pubitemid 28401029)
86. Ramakrishnan R, Fujimura Y, Zou JP, Liu F, Lee L, et al. 2004. Role of protein-protein interactions in the antiapoptotic function of EWS-FLI-1. Oncogene 23:7087-94 (Pubitemid 39319170)
87. Erkizan HV, Kong Y, Merchant M, Schlottmann S, Barber-Rotenberg JS, et al. 2009. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat. Med. 15:750-56
88. Toretsky JA, Erkizan V, Levenson A, Abaan OD, Parvin JD, et al. 2006. Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A. Cancer Res. 66:5574-81 (Pubitemid 43927107)
89. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ. 2005. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 65:8984-92 (Pubitemid 41377390)
90. Stegmaier K, Wong JS, Ross KN, Chow KT, Peck D, et al. 2007. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. PLoSMed. 4:e122
91. DuBois SG, Krailo MD, Lessnick SL, Smith R, Chen Z, et al. 2009. Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group. Pediatr. Blood Cancer 52:324-27
92. Grohar PJ, Woldemichael GM, Griffin LB, Mendoza A, Chen QR, et al. 2011. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. J. Natl. Cancer Inst. 103:962-78
93. Joo J, Christensen L, Warner K, States L, Kang HG, et al. 2009. GLI1 is a central mediator of EWS/FLI1 signaling in Ewing tumors. PLoS ONE 4:e7608
94. Navarro D, Agra N, Pestana A, Alonso J, Gonzalez-Sancho JM. 2010. The EWS/FLI1 oncogenic protein inhibits expression of theWnt inhibitor DICKKOPF-1 gene and antagonizes α-catenin/TCF-mediated transcription. Carcinogenesis 31:394-401
95. Hahm KB, Cho K, Lee C, Im YH, Chang J, et al. 1999. Repression of the gene encoding the TGF-α type II receptor is a major target of the EWS-FLI1 oncoprotein. Nat. Genet. 23:222-27 (Pubitemid 29455398)
96. Im YH, Kim HT, Lee C, Poulin D, Welford S, et al. 2000. EWS-FLI1, EWS-ERG, and EWS-ETV1 oncoproteins of Ewing tumor family all suppress transcription of transforming growth factor αtype II receptor gene. Cancer Res. 60:1536-40 (Pubitemid 30183421)
97. Herrero-Martin D, Osuna D, Ordonez JL, Sevillano V, Martins AS, et al. 2009. Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target. Br. J. Cancer 101:80-90
98. Scotlandi K, Benini S, Sarti M, Serra M, Lollini PL, et al. 1996. Insulin-like growth factor 1 receptor- mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res. 56:4570-74 (Pubitemid 26338048)
99. Yee D, Favoni RE, Lebovic GS, Lombana F, Powell DR, et al. 1990. Insulin-like growth factor 1 expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation.Apotential autocrine growth factor. J. Clin. Investig. 86:1806-14
100. Maki RG. 2010. Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J. Clin. Oncol. 28:4985-95
101. Olmos D, Postel-Vinay S, Molife LR, Okuno SH, Schuetze SM, et al. 2010. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol. 11:129-35
102. Toretsky JA, Gorlick R. 2010. IGF-1R targeted treatment of sarcoma. Lancet Oncol. 11:105-6
103. Kolb EA, Gorlick R. 2009. Development of IGF-IR inhibitors in pediatric sarcomas. Curr. Oncol. Rep. 11:307-13
104. Kurzrock R, Patnaik A, Aisner J, Warren T, Leong S, et al. 2010. A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor 1 receptor antagonist, in patients with advanced solid tumors. Clin. Cancer Res. 16:2458-65
105. Olmos D, Tan DS, Jones RL, Judson IR. 2010. Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside. Cancer J. 16:183-94
106. Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, et al. 2009. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J. Clin. Oncol. 27:5800-7
107. Winter GE, Rix U, Lissat A, Stukalov A, M̈ullner MK, et al. 2011. An integrated chemical biology approach identifies specific vulnerability of Ewing's sarcoma to combined inhibition of Aurora kinases A and B. Mol. Cancer Ther. 10:1846-56
108. Solomon DA, Kim T, Diaz-Martinez LA, Fair J, Elkahloun AG, et al. 2011. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science. 333:1039-43